Study S000160

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes. A Randomized Clinical Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02518945
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 26
Start: 2015-08
Primary completion: 2015-12
Lead sponsor: University at Buffalo
Conditions: Type 1 Diabetes Mellitus
Interventions: DRUG:Dapagliflozin; DRUG:Insulin; DRUG:Liraglutide; DRUG:Dapagliflozin placebo
Results posted: TRUE

Registered primary outcomes

Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. [12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026692	Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes. Kuhadiya ND, The Journal of clinical endocrinology and metabolism	2016	Randomized trial	PMID 27490915 DOI	cites ClinicalTrials.gov:NCT02518945; registry reference DERIVED:27490915